<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107645">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01992263</url>
  </required_header>
  <id_info>
    <org_study_id>IRB #: 1304003801</org_study_id>
    <nct_id>NCT01992263</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation and TB</brief_title>
  <official_title>A Trial of Vitamin D Supplementation Among Tuberculosis Patients in South India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. John's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cornell University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to understand the effects of vitamin D supplementation on
      immunological outcomes among patients with tuberculosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized trial, the investigators will enroll 200 adults with active pulmonary
      tuberculosis (TB; among whom 40 have HIV co-infections) at the time of TB diagnosis in S
      India. The intervention will include daily vitamin D supplementation in 3 treatment arms
      (600, 2000, and 4000 IU vitamin D), compared to placebo, for 12 months. The investigators'
      primary objectives are to assess how vitamin D supplementation affects immunity
      (immunological markers, immune competence) and serum vitamin D levels. Secondary outcomes
      include TB treatment outcomes (successful sputum smear conversion, relapse) in all patients,
      and human immunodeficiency virus (HIV) disease progression among a subset of patients with
      HIV co-infection.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Immune function</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immune responses will be assessed by the superoxide bursts and proteolytic capacities of macrophages and monocytes. Activity indexes will be assessed by comparing mean substrate and calibration fluorescence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell-mediated immunological markers (T cells)</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum 25(OH)D concentrations</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>TB treatment outcomes</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV disease progression</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Vitamin D</condition>
  <condition>Immunity</condition>
  <arm_group>
    <arm_group_label>Vitamin D (600 IU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral dose for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D (2000 IU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral dose for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D (4000 IU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral dose for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily oral dose for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (600 IU)</intervention_name>
    <arm_group_label>Vitamin D (600 IU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (2000 IU)</intervention_name>
    <arm_group_label>Vitamin D (2000 IU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (4000 IU)</intervention_name>
    <arm_group_label>Vitamin D (4000 IU)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active TB diagnosis by GeneXpert

          -  HIV infection status (according to AMC HIV clinic medical records of enzyme-linked
             immunosorbent assay [ELISA] results)

        Exclusion Criteria:

          -  Children (&lt;18 years of age)

          -  60 years of age

          -  Pregnant at baseline

          -  Other severe complications or illnesses requiring hospitalization

          -  Received TB treatment for greater than 4 weeks in the past 5 years

          -  Refused to participate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kenneth, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. John's Research Institute (SJRI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saurabh Mehta, ScD</last_name>
    <phone>607-255-2640</phone>
    <email>smehta@cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elaine Yu, MPH</last_name>
    <phone>714-478-8599</phone>
    <email>eay27@cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>Ithaca</city>
        <state>New York</state>
        <zip>14853</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elaine Yu, MPH</last_name>
      <phone>714-478-8599</phone>
      <email>eay27@cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Saurabh Mehta, ScD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John's Research Institute (SJRI)</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Kenneth, MBBS</last_name>
      <email>johnkennet@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arogyavaram Medical Centre (AMC)</name>
      <address>
        <city>Madanapalle</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bonam Wesley, MBBS</last_name>
      <email>wesleywesleyamc@yahoo.co.in</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>India</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 18, 2013</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>vitamin D</keyword>
  <keyword>immunity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
